Skip to content

Effect of 90% Effective Dose of Metaraminol in Supine and Left Tilt Positions on Cesarean Section

Effect of 90% Effective Dose of Metaraminol in Supine and Left Tilt Positions on Cesarean Section:A Non-inferiority Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05084599
Enrollment
124
Registered
2021-10-20
Start date
2022-05-12
Completion date
2024-01-31
Last updated
2024-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section Complications

Brief summary

For hypotension after spinal anesthesia, metaraminol has different 90% effective doses in the supine position and the left-tilt position. We plan to conduct a non-inferiority trial to compare the effects of the two on the fetus and the mother.

Interventions

DRUGMetaraminol 2.7μg/kg/min

After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.

DRUGMetaraminol 2μg/kg/min

After spinal anesthesia, the patient was placed in left-tilt position until the fetus was delivered, and metaraminol was given at an initial rate of 2μg/kg/min throughout the process.

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

1. Singleton pregnancy at term scheduled to be delivered via elective cesarean delivery; 2. height 150-180 cm; 3. American Society of Anesthesiologists (ASA) physical status II-III; 4. body mass index (BMI) \<35 kg/m2.

Exclusion criteria

1. transverse presentation, fetal macrosomia; 2. uterine abnormalities (eg, large fibroids, bicornuate uterus); 3. polyhydramnios; 4. ruptured membranes, oligohydramnios; 5. intrauterine growth restriction; 6. gestational or nongestational hypertension, diabetes, or eclampsia; 7. hypertensive disorders or any condition associated with autonomic neuropathy (such as diabetes mellitus for \>10 years) or renal failure; 8. contraindications for combined spinal-epidural anesthesia; 9. participants who declined to sign informed consent forms.

Design outcomes

Primary

MeasureTime frameDescription
Umbilical artery blood pH30 seconds after deliverypH value of fetal umbilical artery blood

Secondary

MeasureTime frameDescription
hypotensionIntraoperativeNumber of Participants with systolic blood pressure reduction \>20% baseline value or systolic blood pressure \<90 mm Hg before delivery
bradycardiaIntraoperativeNumber of Participants with heart rate was ≤50 bpm before delivery Number of Participants with heart rate was ≤50 bpm before delivery Number of Participants with heart rate was ≤50 bpm before delivery
The incidence of nausea in pregnant womenIntraoperativeAnesthesiologist observes combined patient dictation.
Umbilical artery blood base excess30sec after deliverybase excess of fetal umbilical artery blood
The incidence of vomiting in pregnant womenIntraoperativeAnesthesiologist observes combined patient dictation

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026